Introduction {#Sec1}
============

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that plays a key role in the development and progression of some tumours, particularly colorectal carcinoma \[[@CR1]\]. It is therefore an attractive target for anticancer therapies. Panitumumab is a fully human monoclonal antibody that targets EGFR \[[@CR2]\]. Studies have shown that panitumumab can significantly improve progression-free survival (PFS) across several lines of treatment in patients with metastatic colorectal cancer (mCRC) whose tumours are wild type (WT) for the *RAS* oncogene (i.e. no detectable mutations in both the *KRAS* and *NRAS* genes) \[[@CR3]--[@CR6]\]. In particular, addition of panitumumab to chemotherapy with leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX, as either the standard FOLFOX4 or the more intensive FOLFOX6 regimen) in first-line treatment has been shown to improve overall survival (OS) versus FOLFOX alone \[[@CR3]\] and versus FOLFOX plus bevacizumab \[[@CR7]\] in patients with WT *RAS* or *KRAS* mCRC. As a result, panitumumab was licensed for the treatment of patients with *RAS* WT mCRC. The licensed indications in Europe are first-line therapy in combination with FOLFOX or FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan), as second-line therapy in combination with FOLFIRI, and as monotherapy after failure of multiple chemotherapy regimens \[[@CR8]\].

Adverse events during cancer treatment can have a negative effect on quality of life (QoL) \[[@CR9], [@CR10]\], and optimal therapy, therefore, involves a balance between efficacy and safety \[[@CR11]\]. Dermatological toxicities such as papulopustular rash (acneiform eruption), erythema, and skin fissures are common side effects of targeted cancer agents such as EGFR inhibitors \[[@CR12]\], as EGFR is involved in the normal development and physiology of the epidermis. It has been reported that emergence of skin toxicity may be a surrogate clinical marker for efficacy of EGFR inhibitors in mCRC, although this remains controversial, with few prospective studies. Studies have also investigated the link between QoL and outcomes in colorectal cancer, showing that baseline QoL is an independent predictor for survival \[[@CR13]\]. In patients receiving panitumumab in combination with FOLFOX, the occurrence of skin toxicity has been correlated with improved survival outcomes in patients with mCRC \[[@CR14]\], but this association is not clear and may be related to the longer duration of treatment in patients responding to panitumumab.

As part of three clinical trials of different lines of treatment with panitumumab in patients with mCRC, QoL data were collected as pre-specified tertiary endpoints: the 20050203 ('PRIME'; NCT00364013) study in first-line treatment of mCRC \[[@CR15]\]; the 20050181 ('181'; NCT00339183) study in second-line treatment \[[@CR16]\]; and the 20020408 ('408'; NCT00113763) study in third- or fourth-line treatment \[[@CR17]\]. Given that skin toxicity is a common side effect of panitumumab, we summarise QoL data from patients with *RAS* WT mCRC in those three studies to investigate a potential relationship between skin toxicity and QoL in patients receiving panitumumab.

Methods {#Sec2}
=======

Study designs and patients {#Sec3}
--------------------------

Full details of the study design and inclusion criteria for the three included studies have been published previously \[[@CR15], [@CR17], [@CR18]\]. All three studies were randomised, open-label phase III trials comparing a standard treatment regimen (PRIME, first-line FOLFOX4; 181, second-line FOLFIRI; 408, best supportive care \[BSC\]) with or without panitumumab. Eligible patients in each study were aged ≥18 years and had an Eastern Cooperative Oncology Group performance status of 0−2. In all three studies the panitumumab dose was 6.0 mg/kg every 2 weeks, and PFS was a primary endpoint. OS was a primary endpoint in the 181 study and a secondary endpoint in the other two studies, with other secondary endpoints in all three studies including objective tumour response and safety. The present analyses use data from the subset of patients with *RAS* WT mCRC from these three studies \[[@CR3]--[@CR5]\].

The protocols of all three studies were approved by the ethics committees at participating sites and adhered to all ethical guidelines, and all patients signed informed consent before any study-related procedures were performed.

Skin toxicity {#Sec4}
-------------

Adverse events were collected throughout treatment and safety follow-up in all three studies and graded according to National Cancer Institute's Common Toxicity Criteria (version 3.0) \[[@CR19]\], with the exception of panitumumab-related skin toxicities, which were graded using a modified version of the CTC version 3.0. Severity of adverse events was rated on a five-point scale: 1 = mild; 2 = moderate; 3 = severe; 4 = life threatening or disabling; and 5 = death.

QoL endpoints and analyses {#Sec5}
--------------------------

QoL was assessed as a pre-specified tertiary endpoint during each study, using the EuroQoL 5-domain (EQ-5D) health state index (HSI) and overall health rating (OHR) measures. HSI scores range from −0.594 to 1.0 (higher scores represent better health, with 1.0 equivalent to perfect health), while OHR comprises a 0−100 visual analogue scale, with 0 representing 'Worst imaginable health state' and 100 representing 'Best imaginable health state'. QoL was assessed ≤7 days before randomisation and every 4 weeks until disease progression, with a final assessment at a safety follow-up visit. For all analyses, minimally important differences (MIDs) were defined as 0.08 for HSI and 7 for OHR \[[@CR20]\]. A descriptive analysis of the distribution of worst skin toxicity grades in patients with a decrease in HSI or OHR exceeding the MID was also performed.

Primary and secondary QoL analyses were conducted on the *RAS* WT patient-reported outcome (PRO) patient cohort, defined as the subsets of *RAS* WT patients in each intent-to-treat analysis set who received at least one dose of study medication, and had a baseline QoL assessment and at least one post-baseline QoL assessment. This is an exploratory analysis without type-I error rate control, and all *p* values are descriptive.

Primary analysis {#Sec6}
----------------

The impact of worst skin toxicity grade on the changes from baseline to discontinuation of treatment in QoL scores was estimated using a linear mixed-effects model for repeated measures \[[@CR21]\]. The mixed-effects model was used for all regression analyses and adjusted for treatment, visit, worst skin toxicity grade, and baseline HSI scores (termed as fixed effects), with intercept and visit as random effects. Worst skin toxicity grade was defined in two different ways in the linear mixed-effect models. In definition 1, between-treatment differences were assessed adjusting for fixed effects terms and significant covariate-by-covariate interactions at the 5 % level. Differences by worst skin toxicity level (grade \<3 vs. ≥3) were evaluated adjusting for fixed effects terms and significant covariate-by-covariate interactions at the 5 % level. Between-treatment differences for each worst skin toxicity level (grade \<3 and ≥3) were assessed using a full model with interactions included. In definition 2, worst skin toxicity was included as a measure over time (i.e. worst skin toxicity grade was assigned to each QoL assessment visit). Covariate-by-covariate interactions were assessed and retained in the model if statistically significant at the 5 % level, and between-treatment differences were assessed adjusting for fixed effect terms and significant interactions.

Secondary analyses {#Sec7}
------------------

In addition to the primary analysis, the distribution of worst skin toxicity grades by treatment arm for all grades was calculated in the subset of patients who had clinically meaningful decreases from baseline in QoL scores. As a sensitivity analysis, the mixed-effect model was repeated without skin toxicity as a covariate, and between-treatment differences were assessed adjusting for treatment, visit, and baseline HSI scores. Demography variables were summarised.

Results {#Sec8}
=======

Patients {#Sec9}
--------

The *RAS* WT PRO sets for PRIME included 232 patients who received panitumumab + FOLFOX4 and 224 who received FOLFOX4 alone; for the 181 study included 187 patients who received panitumumab + FOLFIRI and 194 who received FOLFIRI alone; and for the 408 study included 66 patients who received panitumumab + BSC and 48 who received BSC alone. Baseline demographics, disease characteristics, and QoL scores for patients in the three studies are shown in Table [1](#Tab1){ref-type="table"}. Demographics and disease characteristics were generally similar across studies and between treatment groups, although median QoL scores were lower in the 408 study than in PRIME or 181.Table 1Baseline demographics and disease characteristics (*RAS* wild type, patient-reported outcome intent-to-treat population)PRIME181408Panitumumab + FOLFOX4 (*n* = 232)FOLFOX4 (*n* = 224)Panitumumab + FOLFIRI (*n* = 187)FOLFIRI (*n* = 194)Panitumumab + BSC (*n* = 66)BSC (*n* = 48)Sex Male153 (66)145 (65)120 (64)126 (65)42 (64)32 (67) Female79 (34)79 (35)67 (36)68 (35)24 (36)16 (33)Age (years), median (range)61.0 (27.0, 81.0)61.0 (24.0, 82.0)60.0 (28.0, 81.0)60.5 (33.0, 85.0)61.5 (29.0, 79.0)62.5 (32.0, 81.0)Age group, *n* (%) (years) \<65151 (65)143 (64)116 (62)125 (64)37 (56)29 (60) ≥6581 (35)81 (36)71 (38)69 (36)29 (44)19 (40) \<75213 (92)201 (90)178 (95)182 (94)57 (86)42 (88) ≥7519 (8)23 (10)9 (5)12 (6)9 (14)6 (13)ECOG performance score, *n* (%) 0 or 1221 (95)209 (93)180 (96)184 (95)60 (91)41 (85) 211 (5)15 (7)7 (4)10 (5)6 (9)7 (15)Primary tumour diagnosis, *n* (%) Colon151 (65)148 (66)107 (57)135 (70)45 (68)32 (67) Rectum81 (35)76 (34)80 (43)59 (30)21 (32)16 (33)Site of metastases, *n* (%)N/AN/A Liver only47 (20)34 (15)34 (18)47 (24) Liver + other152 (66)153 (68)127 (68)119 (61) Other only33 (14)37 (17)26 (14)28 (14)Number of metastases, *n* (%)N/AN/A 155 (24)41 (18)38 (20)53 (27) 280 (34)84 (38)70 (37)57 (29) 3+97 (42)99 (44)79 (42)83 (43) Missing0 (0)0 (0)0 (0)1 (\<1)Median EuroQoL score (range) Health state index0.80 (−0.48, 1.00)^a^0.80 (−0.01, 1.00)^c^0.80 (−0.18, 1.00)^e^0.80 (−0.18, 1.00)0.78 (−0.07, 1.00)^h^0.73 (0.09, 1.00)^j^ Overall health rating78.0 (0.0, 100.0)^b^70.0 (6.0, 100.0)^d^75.0 (20.0, 100.0)^f^75.0 (20.00, 100.0)^g^70.5 (29.0, 97.0)^i^60.0 (9.0, 93.0)^ja^ *n* = 229; ^b^ *n* = 227; ^c^ *n* = 222; ^d^ *n* = 219; ^e^ *n* = 186; ^f^ *n* = 182; ^g^ *n* = 190; ^h^ *n* = 62; ^i^ *n* = 60; ^j^ *n* = 45*BSC* best supportive care, *ECOG* Eastern Cooperative Oncology Group, *FOLFIRI* leucovorin, 5-fluorouracil, and irinotecan, *FOLFOX* leucovorin, 5-fluorouracil, and oxaliplatin, *N/A* not available

Overall rates of compliance with QoL assessment (expressed as evaluable vs. expected assessments) were 57 % for both QoL assessments in the PRIME study, 64 % for HSI and 63 % for OHR in 181 study, and 72 % for both QoL assessments in the 408 study.

Quality of life {#Sec10}
---------------

Using skin toxicity definition 1, there were no statistically significant differences between the panitumumab and comparator arms in any of the three studies in terms of HSI or OHR scores from baseline to discontinuation (Table [2](#Tab2){ref-type="table"}a). The between-group difference for HSI in the 408 study, however, was larger than the MID of 0.08, favouring BSC alone. Results were similar when using definition 2 (Table [2](#Tab2){ref-type="table"}b) and when skin toxicity was removed from the mixed-effect model (Online Resource 1).Table 2Mixed-effect linear model of change from baseline to discontinuation of treatment in EuroQoL 5-domain health state index and overall health rating scores using skin toxicity a) definition 1 and b) definition 2PRIME181408Panitumumab + FOLFOX4FOLFOX4Panitumumab + FOLFIRIFOLFIRIPanitumumab + BSCBSC*(a)*Health state index*n* = 224*n* = 221*n* = 186*n* = 194*n* = 61*n* = 45 Adjusted LS mean−0.0050.006−0.0280.017−0.0030.108 95 % confidence intervals−0.027, 0.017−0.022, 0.034−0.052, −0.004−0.049, 0.014−0.076, 0.070−0.103, 0.319 Difference−0.011 (−0.042, 0.020)−0.011 (−0.047, 0.025)−0.111 (−0.323, 0.101) *p* value0.500.560.30Overall health rating*n* = 222*n* = 218*n* = 182*n* = 190*n* = 59*n* = 45 Adjusted LS mean−0.910.73−1.19−0.73−0.28−0.59 95 % confidence intervals−2.77, 0.96−1.67, 3.14−2.90, 0.51−2.89, 1.43−4.08, 3.51−6.35, 5.16 Difference−1.64 (−4.26, 0.98)−0.47 (−2.85, 1.92)0.31 (−4.54, 5.15) *p* value0.220.700.90*(b)*Health state index*n* = 224*n* = 221*n* = 186*n* = 194*n* = 61*n* = 44 Adjusted LS mean0.0210.041−0.027−0.016−0.0480.175 95 % confidence intervals−0.014, 0.0570.003, 0.079−0.085, 0.032−0.076, 0.044−0.116, 0.019−0.039, 0.388 Difference−0.019 (−0.050, 0.012)−0.011 (−0.047, 0.026)−0.223 (−0.457, 0.010) *p* value0.220.570.06Overall health rating*n* = 222*n* = 218*n* = 182*n* = 190*n* = 59*n* = 44 Adjusted LS mean−1.650.40−0.74−0.48−3.291.24 95 % confidence intervals−4.25, 0.95−2.36, 3.16−4.58, 3.11−4.41, 3.45−7.18, 0.59−7.00, 9.49 Difference−2.05 (−4.59, 0.49)−0.26 (−2.72, 2.20)−4.54 (−14.60, 5.53) *p* value0.110.840.38*BSC* best supportive care, *FOLFIRI* leucovorin, 5-fluorouracil, and irinotecan, *FOLFOX* leucovorin, 5-fluorouracil, and oxaliplatin, *LS* least squares

Skin toxicity {#Sec11}
-------------

The most common skin toxicities in the three studies are shown in Table [3](#Tab3){ref-type="table"}a, with the distribution of worst skin toxicity grades by treatment in each study shown in Fig. [1](#Fig1){ref-type="fig"}. In the PRIME study, 5 % of patients overall discontinued treatment because of skin toxicities (panitumumab + FOLFOX, 8 %; FOLFOX, 1 %). In the 181 study, 4 % of patients overall discontinued treatment because of skin toxicities (panitumumab + FOLFIRI, 7 %; FOLFIRI, 0.5 %). The median number of treatment cycles received before discontinuation because of skin toxicity in the PRIME study was seven in the panitumumab + FOLFOX arm and 12 in the FOLFOX arm. The median number of treatment cycles received before discontinuation because of skin toxicity in the 181 study was five in the panitumumab + FOLFIRI arm and one in the FOLFIRI arm. The most common skin toxicities leading to discontinuation in the PRIME and 181 studies are shown in Table [3](#Tab3){ref-type="table"}b. No patient discontinued because of skin toxicity in the 408 study.Table 3(a) Most common skin toxicities (≥10 % of patients in any treatment arm) and (b) discontinuations because of skin toxicity (\>1 patient in any treatment arm)Skin toxicity (MedDRA preferred term), *n* (%)PRIME181408Panitumumab + FOLFOX4 (*n* = 232)FOLFOX4 (*n* = 224)Panitumumab + FOLFIRI (*n* = 187)FOLFIRI (*n* = 194)Panitumumab + BSC (*n* = 65)BSC (*n* = 48)*(a)*Rash131 (56)17 (8)105 (56)17 (9)12 (18)1 (2)Dermatitis acneiform83 (36)055 (29)2 (1)45 (69)0 (0)Pruritus63 (27)11 (5)40 (21)8 (4)51 (78)2 (4)Dry skin56 (24)9 (4)40 (21)11 (6)10 (15)0 (0)Skin fissures43 (19)1 (\<1)38 (20)1 (1)22 (34)0 (0)Erythema42 (18)8 (4)27 (14)6 (3)49 (75)1 (2)Acne36 (16)1 (\<1)29 (16)4 (2)13 (20)0 (0)Palmar--plantar erythrodysaesthesia syndrome24 (10)7 (3)20 (11)10 (5)1 (2)0 (0)Exfoliative rash7 (3)3 (1)6 (3)0 (0)20 (31)0 (0)Skin toxicity (MedDRA preferred term), *n* (%)PRIME181Panitumumab + FOLFOX4FOLFOX4Panitumumab + FOLFIRIFOLFIRI*(b)*Rash10 (4)0 (0)6 (3)0 (0)Dermatitis acneiform4 (2)0 (0)0 (0)0 (0)Acne1 (1)0 (0)2 (1)0 (0)No patient in the 408 study discontinued because of skin toxicity*BSC* best supportive care, *FOLFIRI* leucovorin, 5-fluorouracil, and irinotecan, *FOLFOX* leucovorin, 5-fluorouracil, and oxaliplatin, *MedDRA* Medical Dictionary for Regulatory ActivitiesFig. 1Distribution of worst skin toxicity by treatment arm in each study

Analysis of quality of life by skin toxicity {#Sec12}
--------------------------------------------

Using skin toxicity definition 1, there were no statistically or clinically significant differences in QoL outcomes between patients with worst skin toxicity of grade \<3 and those with grade ≥3 in any of the three studies (Table [4](#Tab4){ref-type="table"}). In addition, there were no statistically significant differences between the panitumumab and comparator arms in subgroups of patients with worst skin toxicity grade \<3 (Table [5](#Tab5){ref-type="table"}), although the between-group difference in HSI in the 408 study (−0.112) was greater than the MID in favour of BSC. In the PRIME and 181 studies, there were no statistically significant differences between the panitumumab and comparator arms in patients with worst skin toxicity grade of ≥3, although the difference in OHR in the 181 study (−8.21) was greater than the MID in favour of FOLFIRI alone (Table [5](#Tab5){ref-type="table"}). In the 408 study, no patient in the BSC alone arm experienced grade ≥3 skin toxicity, so no comparison was possible.Table 4Mixed-effect linear model of change from baseline to discontinuation of treatment in EuroQoL 5-domain health state index and overall health rating scores by worst skin toxicity grade (skin toxicity definition 1)PRIME\
Worst skin toxicity grade181\
Worst skin toxicity grade408\
Worst skin toxicity grade\<3≥3\<3≥3\<3≥3Health state index*n* = 351*n* = 94*n* = 299*n* = 81*n* = 95*n* = 11 Adjusted LS mean0.007−0.006−0.024−0.0220.0290.076 95 % confidence intervals−0.012, 0.025−0.040, 0.029−0.044, −0.004−0.059, 0.016−0.077, 0.135−0.078, 0.229 Difference0.0123 (−0.026, 0.050)−0.003 (−0.046, 0.041)−0.047 (−0.170, 0.076) *p* value0.520.910.45Overall health rating*n* = 348*n* = 92*n* = 294*n* = 78*n* = 93*n* = 11 Adjusted LS mean−0.02−0.15−1.33−0.59−3.082.21 95 % confidence intervals−1.61, 1.56−3.03, 2.74−2.78, 0.11−3.20, 2.03−6.27, 0.10−4.87, 9.29 Difference0.13 (−3.03, 3.29)−0.75 (−3.65, 2.15)−5.29 (−12.3, 1.71) *p* value0.940.610.14*LS* least squaresTable 5Mixed-effect linear model of change from baseline to discontinuation of treatment in EuroQoL 5-domain health state index and overall health rating scores by treatment group and worst skin toxicity grade in the (a) PRIME, (b) 181, and (c) 408 studies (skin toxicity definition 1)Worst skin toxicity grade\<3≥3Panitumumab + FOLFOX4FOLFOX4Panitumumab + FOLFOX4FOLFOX4*(a)*Health state index*n* = 136*n* = 215*n* = 88*n* = 6 Adjusted LS mean−0.0030.011−0.0040.009 95 % confidence intervals−0.033, 0.027−0.014, 0.036−0.040, 0.032−0.116, 0.134 Difference−0.015 (−0.053, 0.024)−0.013 (−0.140, 0.114)Overall health rating*n* = 136*n* = 212*n* = 86*n* = 6 Adjusted LS mean−0.300.66−1.562.10 95 % confidence intervals−2.83, 2.23−1.46, 2.78−4.66, 1.54−8.36, 12.57 Difference−0.96 (−4.23, 2.32)−3.66 (−14.30, 6.98)Worst skin toxicity grade\<3≥3Panitumumab + FOLFIRIFOLFIRIPanitumumab + FOLFIRIFOLFIRI*(b)*Health state index*n* = 111*n* = 188*n* = 75*n* = 6 Adjusted LS mean−0.019−0.022−0.0380.032 95 % confidence intervals−0.051, 0.014−0.047, 0.004−0.074, −0.001−0.100, 0.164 Difference0.003 (−0.038, 0.044)−0.070 (−0.206, 0.066)Overall health rating*n* = 110*n* = 184*n* = 72*n* = 6 Adjusted LS mean−2.10−0.61−1.396.82 95 % confidence intervals−4.47, 0.26−2.53, 1.32−4.15, 1.38−2.04, 15.68 Difference−1.50 (−4.53, 1.53)−8.21 (−17.26, 0.85)Worst skin toxicity grade\<3≥3Panitumumab + BSCBSCPanitumumab + BSCBSC*(c)*Health state index*n* = 50*n* = 45*n* = 11*n* = 0 Adjusted LS mean−0.0270.0840.026− 95 % confidence intervals−0.096, 0.042−0.122, 0.291−0.146, 0.199− Difference−0.112 (−0.329, 0.106)−Overall health rating*n* = 48*n* = 45*n* = 11*n* = 0 Adjusted LS mean−2.47−3.083.54− 95 % confidence intervals−5.72, 0.77−14.57, 8.41−3.51, 10.59− Difference0.60 (−11.36, 12.57)−*BSC* best supportive care, *FOLFIRI* leucovorin, 5-fluorouracil, and irinotecan, *FOLFOX* leucovorin, 5-fluorouracil, and oxaliplatin, *LS* least squares

The distributions of worst skin toxicity grades in patients with a decrease in QoL greater than the MIDs for HSI or OHR are shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Distribution of worst skin toxicity by treatment arm in each study in patients who had clinically meaningful decreases of **a** ≥0.08 points in HSI and **b** ≥7 points in overall health rating

Discussion {#Sec13}
==========

While the addition of panitumumab to chemotherapy or BSC is associated with skin toxicity---as demonstrated by the distribution of worst grade skin toxicity in each treatment arm---results from these analyses show no statistically significant negative impact of panitumumab treatment on overall QoL. In addition, there was no apparent difference in distribution of worst skin toxicity grade in patients with a decrease in QoL compared with the overall population.

In first- and second-line therapy, addition of panitumumab to chemotherapy had no clinically significant impact on overall QoL. Indeed, a recent quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis from the PRIME study showed that panitumumab plus FOLFOX4 significantly improved quality-adjusted survival time compared with FOLFOX4 alone (20.5 vs. 18.2 months, respectively; *p* = 0.025) \[[@CR22]\]. In later lines of therapy (408 study), the difference in HSI between the panitumumab plus BSC and BSC alone arms (−0.111 and −0.223 for skin toxicity definitions 1 and 2, respectively) was greater than the MID (0.08), although not statistically significant. This is in contrast to an earlier analysis of QoL in the *KRAS* WT population of the 408 study, which showed a small, but clinically significant benefit for panitumumab plus BSC over BSC alone on the EQ-5D HSI \[[@CR23]\]. Furthermore, a previous Q-TWiST analysis of PFS and OS in the 408 study showed that panitumumab plus BSC significantly improved quality-adjusted survival compared with BSC alone in patients with *KRAS* WT mCRC \[[@CR24]\]. Importantly, the small patient cohort in the 408 study should be taken into account when interpreting the results reported here. In addition, while a clinically meaningful difference between the panitumumab plus FOLFIRI and FOLFIRI alone arms was observed for patients with worst skin toxicity grade ≥3 in the 181 study, this is probably the result of the small number of patients in the FOLFIRI arm with skin toxicity of grade ≥3.

While skin toxicity might be expected to have a negative impact on QoL, there were no statistically or clinically significant differences in QoL between patients with worst skin toxicity grade \<3 and those with grade ≥3 in these exploratory analyses. Furthermore, few patients discontinued as a result of skin toxicity in any of the three studies. While skin toxicity had no impact on global QoL, it is important to note that it remains a clinically relevant adverse event that requires proactive management \[[@CR12]\].

Overall, our results are consistent with previous studies of first- and second-line EGFR inhibitor therapy in mCRC. For example, similar results were seen in an earlier analysis of QoL data from patients with *KRAS* WT mCRC in the PRIME study \[[@CR25]\], as well as in a recent analysis of EQ-5D subscales \[[@CR26]\]. In studies of first-line FOLFIRI combined with panitumumab or cetuximab, another EGFR inhibitor licensed for treatment of mCRC, no negative effect on QoL or social functioning has been observed during treatment \[[@CR27], [@CR28]\]. Similarly, a study of panitumumab added to second-line FOLFIRI showed that panitumumab improved PFS without compromising QoL \[[@CR24]\]. A study of the psychological effects associated with cetuximab treatment in 80 consecutive patients treated at a single centre (any treatment line) showed that psychological distress was present in 41 % of patients \[[@CR29]\]. Notably, there was a link between distress and overall QoL, but distress was not specifically linked with rash, which did not affect psychological status or social life. In another cetuximab study, patients with mCRC experienced psychological distress initially, as they processed their cancer diagnosis and dermatological side effects at the same time \[[@CR30]\]. Later in the course of treatment, however, skin reactions no longer had a significant influence on health-related QoL, possibly because patients link the development of skin toxicities with the action of the drug and, by association, the probability of an effective treatment response.

The QoL scales used in these studies, including the EQ-5D, are measures of global QoL and are not specific for skin toxicity. The negative impact of rash-related events may therefore have been balanced by treatment-related effects, particularly in patients receiving earlier lines of therapy. For example, as noted above, patients with advanced cancer may consider skin rash to be part of their overall condition or to be a marker of efficacy \[[@CR29], [@CR30]\]. It is also possible that the beneficial effects of treatment---relating, for example, to symptom relief \[[@CR26]\]---may outweigh skin-related side effects \[[@CR10]\]. It should also be noted that rash is an expected adverse event with EGFR inhibitors, which means that physicians are able to discuss it with their patients in advance and initiate prophylactic therapy and proactive management of symptoms. The lack of a difference in QoL associated with different grades of skin toxicity suggests, however, that QoL tools specific for skin-related events are required to assess the direct effect of skin toxicity on QoL for patients receiving EGFR inhibitors.

In conclusion, the addition of panitumumab to chemotherapy in first- or second-line *RAS* WT mCRC has no negative effect on overall QoL, despite the occurrence of skin toxicity. In later lines of therapy, addition of panitumumab monotherapy to BSC was associated with no statistically significant negative effect on QoL, although some between-treatment differences were greater than the MID. In all three studies, skin toxicity of a worst grade of ≥3 appeared to have similar impact on QoL outcomes as skin toxicity of grade \<3. While skin toxicity had no impact on overall QoL, it is a clinically relevant adverse event that requires proactive management. It should also be noted that the QoL scale used in these studies was a generic questionnaire, and differences may have been observed if a skin-specific QoL instrument had been used. Further research is needed, using QoL tools specific for skin-related events, to assess the direct effect of skin toxicity on QoL for patients receiving EGFR inhibitors.
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